title: [Efficacy of hepatitis B vaccination on hepatitis B prevention and on hepatocellular carcinoma].
abstract: OBJECTIVE
  To evaluate the efficacy of hepatitis B vaccination on hepatitis B prevention and on hepatocellular carcinoma.
  
  
  METHODS
  Birth cohort study, cross-sectional seroepidemiological survey, and surveillance of hepatitis B (HBV) and hepatocellular carcinoma were used to evaluate the efficacy of hepatitis B vaccination.
  
  
  RESULTS
  During the 14 years after hepatitis B vaccination, the HBsAg positive rates were found to be 0.7% - 2.9%, with an average of 1.5%, and the protective rates were 83.5% - 96.6%. Hepatitis B virus infection rates of children immunized with hepatitis B vaccine were 1.1% - 5.1%, with an average of 2.2% and the protective rates of 93.5% - 98.4%. 15 years after hepatitis B vaccination, the incidence of hepatitis B dropped from 3.27/10 000 to 0.17/10 000, a 94.8% decrease, in the group of 0 - 19 year-olds.
  
  
  CONCLUSIONS
  The universal infant hepatitis B vaccination has proved to be effective in reducing the incidence rate of acute hepatitis B as well as the mortality of hepatocellular carcinoma.
authors.affiliation: Center for Disease Prevention and Control, Guangxi Zhuangzu Autonimous Region, Nanning 530021, China.
authors.forename: Rong-cheng
authors.initials: RC
authors.lastname: Li
authors.forename: Jin-ye
authors.initials: JY
authors.lastname: Yang
authors.forename: Jian
authors.initials: J
authors.lastname: Gong
authors.forename: Yan-ping
authors.initials: YP
authors.lastname: Li
authors.forename: Zhao-neng
authors.initials: ZN
authors.lastname: Huang
authors.forename: Kong-xiong
authors.initials: KX
authors.lastname: Fang
authors.forename: Zhi-yi
authors.initials: ZY
authors.lastname: Xu
authors.forename: Chong-bai
authors.initials: CB
authors.lastname: Liu
authors.forename: Kai
authors.initials: K
authors.lastname: Zhao
authors.forename: Hui
authors.initials: H
authors.lastname: Zhuang
mesh_terms: D000293:Adolescent; D000328:Adult; D006528:Carcinoma, Hepatocellular / Q000453:epidemiology / Q000517:prevention & control* / Q000821:virology; D002648:Child; D002675:Child, Preschool; D002681:China / Q000453:epidemiology; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D006509:Hepatitis B / Q000453:epidemiology / Q000517:prevention & control*; D017325:Hepatitis B Vaccines / Q000276:immunology; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D008113:Liver Neoplasms / Q000453:epidemiology / Q000517:prevention & control* / Q000821:virology; D008875:Middle Aged; D015995:Prevalence; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000276:immunology
chemical_list: D017325:Hepatitis B Vaccines; D014614:Vaccines, Synthetic